A61P 11/14
Antitussive agents
A61P11/14 (Antitussive agents) appears on 1,168 US grants and 1,663 published applications in this corpus.
Search patents in A61P- Granted patents
- 1,168
- Published applications
- 1,663
- Assignees
- 633
- Inventors
- 3,359
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 7 | 0 |
| 1977 | 5 | 0 |
| 1978 | 1 | 0 |
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 5 | 0 |
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 5 | 0 |
| 1985 | 7 | 0 |
| 1986 | 5 | 0 |
| 1987 | 5 | 0 |
| 1988 | 10 | 0 |
| 1989 | 11 | 0 |
| 1990 | 9 | 0 |
| 1991 | 5 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 5 | 0 |
| 1995 | 10 | 0 |
| 1996 | 5 | 0 |
| 1997 | 5 | 0 |
| 1998 | 8 | 0 |
| 1999 | 18 | 0 |
| 2000 | 6 | 0 |
| 2001 | 10 | 5 |
| 2002 | 21 | 30 |
| 2003 | 19 | 58 |
| 2004 | 28 | 74 |
| 2005 | 26 | 58 |
| 2006 | 32 | 73 |
| 2007 | 27 | 66 |
| 2008 | 26 | 88 |
| 2009 | 37 | 98 |
| 2010 | 36 | 106 |
| 2011 | 71 | 110 |
| 2012 | 71 | 127 |
| 2013 | 79 | 68 |
| 2014 | 72 | 83 |
| 2015 | 61 | 81 |
| 2016 | 68 | 75 |
| 2017 | 55 | 80 |
| 2018 | 68 | 78 |
| 2019 | 53 | 61 |
| 2020 | 39 | 51 |
| 2021 | 27 | 40 |
| 2022 | 24 | 38 |
| 2023 | 25 | 40 |
| 2024 | 19 | 35 |
| 2025 | 16 | 25 |
| 2026 | 9 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Amino quinazoline derivatives as P2X3 inhibitors26 May 2026US 12,637,451 B2Chiesi Farmaceutici S.P. A.
- Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator26 May 2026US 12,637,452 B2GlaxoSmithKline Intellectual Property (No. 3) Limited
- Agave syrup formulation or suspension for active pharmaceutical agents19 May 2026US 12,629,422 B2Genexa Inc.
- Linear polysaccharide based film products12 May 2026US 12,622,971 B2Aquestive Therapeutics, Inc.
- Pyridopyrimidines derivatives as P2X3 inhibitors21 Apr 2026US 12,606,562 B2Chiesi Farmaceutici S.P. A.
- Farfarae flos and asteris radix et rhizoma cough-relieving granule composition and preparation method therefor30 Jul 2026US 2026/0216275 A1Jiangzhong Pharmaceutical Co., Ltd.
- Solid dispersion of compound having p2x4 receptor antagonistic action23 Jul 2026US 2026/0207620 A1Nippon Chemiphar Co., Ltd.
- Pharmaceutical composition of kappa opioid receptor agonist, preparation method therefor, and use thereof23 Jul 2026US 2026/0207699 A1Yichang Humanwell Pharmaceutical Co., Ltd.
- Anti-il5r antibody formulations16 Jul 2026US 2026/0199462 A1
- Keratin cf1, preparation method therefor, pharmaceutical composition comprising same, and use thereof16 Jul 2026US 2026/0201002 A1Institute of Materia Medica, Chinese Academy of Medical Sciences
Most cited
By later US patents
- Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension648US 5,674,533 ARecordati S.A., Chemical and Pharmaceutical Company · 1997
- Controlled release bases for pharmaceuticals383US 4,861,598 AEuroceltique, S.A. · 1989
- Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents342US 6,309,663 B1Lipocine Inc. · 2001
- Fast dissolving orally comsumable films222US 6,596,298 B2Warner-Lambert Company · 2003
- Aerosol metering valve157US 7,168,597 B1SmithKline Beecham Corporation · 2007